Stephen Brady, Tempest Therapeutics CEO
Tempest eyes pivotal trial for liver cancer drug after unveiling early PFS, OS data
Months after initial data suggested Tempest Therapeutics’ drug, when given on top of Roche’s Avastin and Tecentriq, can help shrink liver cancer, the company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.